Form 4: Esperion Therapeutics CFO Sells Shares to Cover Tax Obligations

Esperion Therapeutics' Chief Financial Officer, Benjamin Halladay, sold 9 shares of common stock to cover tax obligations related to vested restricted stock units.

Summary

• Benjamin Halladay, the Chief Financial Officer of Esperion Therapeutics, Inc., sold 9 shares of common stock on January 17, 2025.
• The sale was executed at a price of $2.265 per share.
• This transaction reduced Halladay's direct holdings to 240,682 shares.
• The sale was conducted to satisfy tax obligations arising from the vesting of restricted stock units.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction for tax purposes and does not indicate any significant positive or negative sentiment.

Industry Context

This is a routine transaction for a company officer to sell shares to cover tax obligations. It is common for executives to receive stock-based compensation, which can trigger tax liabilities upon vesting.

Comparison to Industry Standards

• Executive stock sales to cover tax obligations are a common practice across the industry.
• Many companies use restricted stock units as part of their compensation packages, leading to similar tax-related sales by executives.
• The number of shares sold is small relative to the total holdings, suggesting this is a routine tax-related transaction rather than a significant change in sentiment.

Stakeholder Impact

• The sale is unlikely to have a significant impact on shareholders as it is a small transaction by an executive to cover tax obligations.

Key Dates

Keywords

Esperion Therapeutics, Benjamin Halladay, Chief Financial Officer, stock sale, Form 4, insider trading, tax obligations, restricted stock units